Meta-Analysis In Lancet Projects End of Beta-Blockers For Hypertension
Beta-blockers should not remain the first-line therapy for high blood pressure, researchers of a study published in the Oct. 18 Lancet said
You may also be interested in...
FDA is planning to include clinical outcomes data in antihypertensive labeling in light of findings from the ALLHAT and LIFE studies
Merck Cozaar data from the LIFE study support a risk reduction claim for strokes rather than a broader new indication, FDA Office of Medical Policy Director Robert Temple, MD, said
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011